CAS: 857036-77-2; Cediranib Maleate

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

  • 合成目标产物 Cediranib Maleate 主要起始原料 7-(Benzyloxy)-4-(4-Fluoro-2-Methyl-1H-Indol-5-Yloxy)-6-Methoxyquinazoline
  • (文献来源)合成步骤主要原料 7-(Benzyloxy)-4-(4-Fluoro-2-Methyl-1H-Indol-5-Yloxy)-6-Methoxyquinazoline
7-(苄氧基)-4-(4-氟-2-甲基-1H-吲哚-5-氧基)-6-甲氧基喹唑啉置于palladium 10% On Activated Carbon,氢气,Potassium Carbonate,甲烷体系中,用 N-甲基吡咯烷酮,异丙醇 作为反应溶剂,20.0~80.0 °C,101.33 Kpa 条件下,反应 8.08H,反应生成 西地尼布马来酸盐
参考文献:西地尼布盐及其晶型,以及其制备方法和药物组合物
标题:西地尼布盐及其晶型,以及其制备方法和药物组合物
摘要:本发明涉及西地尼布盐及其晶型,与现有技术相比,本发明的西地尼布盐及其晶型在水中具有更好的溶解度.本发明还涉及所述西地尼布盐及其晶型的制备方法,其药物组合物及其在制备用于治疗和/或预防病理性血管反应生成疾病的药物中的用途.

海关参考信息

专利信息


专利号:WO-2025128098-A1
优先权日:2023-12-13
标 题 :Solid oral dosage forms, kits, and methods of using the same
发明人:LI YING; LANGER ROBERT; TRAVERSO CARLO
权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

专利号:US-12180228-B2
优先权日:2019-06-05
标题:Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
发明人:MOVASSAGHI MOHAMMAD; OLSSON CHASE ROBERT; SCOTT TONY Z; CHEAH JAIME; PAYETTE JOSHUA NATHANIEL
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.

专利号:EP-3645600-A1
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof

专利号:CN-102603718-B
优先权日:2012-02-08
标 题:Synthesis method of cediranib
台州市适泽化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.seasonsbio.com/
电话: 0576-0576-89232655 13566878689👤
📞台州市适泽化工有限公司 ⚠️参考联系方式

销售电话:0576-0576-89232655 13566878689
邮箱:info@seasonsbio.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

台州市方远大厦商务楼1503室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Al-Huniti N, Petersson K, Tang W, Masson E, Li J. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer. Br J Clin Pharmacol. 2017 Dec 22. doi: 10.1111/bcp.13495. [Epub ahead of print] pii: 20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12.
3: Orbegoso C, Marquina G, George A, Banerjee S. The role of Cediranib in ovarian cancer. Expert Opin Pharmacother. 2017 Oct;18(15):1637-1648. doi: 10.1080/14656566.2017.1383384. doi: 10.1016/j.jtho.2017.05.021. Epub 2017 Jun 6.
5: Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知